^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    azacitidine

    i
    Other names: U-18496, Aza-C, NS 17, NS-17, Aza C, NSC-102816
    Company:
    Generic mfg.
    Drug class:
    DNMT inhibitor
    Related drugs:
    17h
    Venetoclax Combined With Azacitidine for Consolidation Therapy in AML (clinicaltrials.gov)
    P2, N=216, Recruiting, The First Affiliated Hospital of Soochow University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • cytarabine • azacitidine
    18h
    BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, University of Illinois at Chicago | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint® • EndoPredict®
    |
    azacitidine
    1d
    EP0042-101: Study to Evaluate the Safety and Tolerability of EP0042 (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Ellipses Pharma | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Oct 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Venclexta (venetoclax) • azacitidine • EP0042
    5d
    Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study. (PubMed, Cancer)
    Selinexor combined with azacitidine or ruxolitinib showed encouraging efficacy with a manageable safety profile in patients with MDS/MPN.
    Journal
    |
    XPO1 (Exportin 1)
    |
    azacitidine • Jakafi (ruxolitinib) • Xpovio (selinexor)
    6d
    Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML (clinicaltrials.gov)
    P3, N=60, Completed, The First Affiliated Hospital of Soochow University | Recruiting --> Completed | N=30 --> 60 | Trial completion date: Mar 2025 --> Feb 2026
    Trial completion • Enrollment change • Trial completion date
    |
    Venclexta (venetoclax) • azacitidine
    7d
    Venetoclax and hypomethylating agents synergize to increase cell death and metabolic remodeling in acute B-lymphoblastic leukemia cells. (PubMed, Mol Metab)
    Overexpression of anti-apoptotic protein BCL-2 and hypermethylation are hallmarks of acute lymphoblastic leukemia (ALL) and can be pharmacologically addressed by venetoclax (VEN) and hypomethylating agents (HMA) such as azacytidine (AZA) or decitabine (DEC). AZA-induced metabolic suppression as well as overall anti-leukemic activity alone and in combination with VEN was generally weaker compared to DEC. Altogether, we herein demonstrate that combined VEN and HMA application acts synergistically and significantly reduces the leukemic burden in ALL cell lines via impairment of tumor cell metabolism and mitochondrial function.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • azacitidine • decitabine
    7d
    Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=450, Enrolling by invitation, First Affiliated Hospital of Zhejiang University
    New P2/3 trial
    |
    azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin
    7d
    Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=267, Enrolling by invitation, First Affiliated Hospital of Zhejiang University
    New P2/3 trial
    |
    azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin
    8d
    Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, Liping Dou
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    cytarabine • azacitidine • Epidaza (chidamide)
    8d
    A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm (clinicaltrials.gov)
    P2, N=0, Withdrawn, M.D. Anderson Cancer Center | Trial completion date: Aug 2029 --> Jun 2026 | Trial primary completion date: Aug 2027 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    azacitidine • Rezlidhia (olutasidenib)
    9d
    Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia (clinicaltrials.gov)
    P2, N=120, Recruiting, Chinese PLA General Hospital | Trial primary completion date: Dec 2027 --> Sep 2027
    Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • daunorubicin • aclarubicin
    9d
    A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    azacitidine • Besremi (ropeginterferon alfa-2b-njft)